GlaxoSmithKline Pakistan Limited reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was PKR 11,860.21 million compared to PKR 9,542.38 million a year ago. Net loss was PKR 752.39 million compared to PKR 293.83 million a year ago. Basic loss per share from continuing operations was PKR 2.36 compared to PKR 0.92 a year ago.
For the six months, sales was PKR 23,259.33 million compared to PKR 18,168.34 million a year ago. Net loss was PKR 321.83 million compared to net income of PKR 631.21 million a year ago. Basic loss per share from continuing operations was PKR 1.01 compared to basic earnings per share from continuing operations of PKR 1.98 a year ago.